282 related articles for article (PubMed ID: 16494932)
1. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
2. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
3. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
4. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
Molpus KL; Anderson LB; Craig CL; Puleo JG
Gynecol Oncol; 2004 May; 93(2):513-6. PubMed ID: 15099971
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
[TBL] [Abstract][Full Text] [Related]
7. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
[TBL] [Abstract][Full Text] [Related]
8. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
Kanis M; Kesterson JP; Lele S
Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
[TBL] [Abstract][Full Text] [Related]
9. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
10. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
[TBL] [Abstract][Full Text] [Related]
11. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
[TBL] [Abstract][Full Text] [Related]
12. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
13. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
Drake RD; Lin WM; King M; Farrar D; Miller DS; Coleman RL
Gynecol Oncol; 2004 Aug; 94(2):320-4. PubMed ID: 15297168
[TBL] [Abstract][Full Text] [Related]
14. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Rossi D; Catalano G
Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
[No Abstract] [Full Text] [Related]
15. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Markman M; Kulp B; Peterson G
Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
[TBL] [Abstract][Full Text] [Related]
16. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Li Y; Finkel KW; Hu W; Fu S; Liu J; Coleman R; Kavanagh JJ
Gynecol Oncol; 2007 Aug; 106(2):375-80. PubMed ID: 17512575
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
[TBL] [Abstract][Full Text] [Related]
19. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]